Amarin Corporation PLC
Change company Symbol lookup
Select an option...
AMRN Amarin Corporation PLC
ABBV Abbvie Inc
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
PDI PIMCO Dynamic Income Fund
Go

Health Care : Biotechnology |
Based in Ireland
Company profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$1.12
Day's Change
-0.05 (-4.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.19
Day's Low
1.12
Volume
(Light)
Volume:
1,438,939

10-day average volume:
2,250,875
1,438,939

Display:

Providers:

UpdateCancel
4 providers
November 07, 2022
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.(Zacks)

November 03, 2022
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.(Zacks)

Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.(Zacks)

June 06, 2022
Amarin stock surges after plan to cut total workforce by 40%

Shares of Amarin Corp. (AMRN) hiked up 5.4% in premarket trading Monday, after the drug maker said it would reduce its workforce by 40% as part of its plan to cut operating costs by $100 million over the next 12 months. The cuts would represent...(MarketWatch)

Amarin to cut U.S. commercial team by 65%, total workforce by 40%

(END) Dow Jones Newswires June 06, 2022 08:46 ET (12:46 GMT) (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.